ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

NCI Programs: 15 New Grants Awarded In Survivor Research

October 9, 1998

Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer

January 31, 2003

Letter To The Editor: Prevention Research Requires Rigor And Collaboration.

June 20, 2003

Schweiker Approves Chabner Appointment

September 10, 1982

ODAC Prefers Three-Hour Taxol Infusion. Says Data Dosage Still Uncertain

October 1, 1993

ADT May Increase Risk Of Cardio Events In Prostate Cancer Patients

February 5, 2010